Cetuximab / panitumumab
About one-third of all epithelial cancers express high levels of epidermal growth factor receptor (EGF-R). Expression of EGF-R in a tumor is an indicator of poor prognosis, decreased survival, and increased metastasis.
Cetuximab (Erbitux®) is a monoclonal antibody directed against this EGF-R. By binding to this receptor, cetuximab blocks phosphorylation
The side effects can be very serious and may include allergic reactions. Other more common side effects of cetuximab treatment includes acne-like rash and dry skin.